Treatment outcome analysis of bevacizumab combined with cyclophosphamide and oxaliplatin in advanced pseudomyxoma peritonei

Table 1 Clinicopathological characteristics of 32 pseudomyxoma peritonei patients

Characteristic	No. of patients (%)
Sex
Male	24 (75)
Female	8 (25)
Age (years), median (rang)	57.5 (34-74)
BSA (m2), median (rang)	1.69 (1.27-2.07)
KPS score, median (rang)	90 (60-100)
PCI score, median (rang)	31 (16-39)
Ca199 before chemotherapy, median (rang), U/mL	46.09 (4.68-10707.5)
CEA before chemotherapy, median (rang), ng/mL	16.63 (1.08-632.27)
Ca125 before chemotherapy, median (rang), U/mL	26.25 (5.3-146.7)
CC score
0-1	8 (25)
2-3	24 (75)
Histological diagnosis
Low-grade	12 (37.5)
High-grade	18 (56.2)
High-grade with signet ring cells	2 (6.3)
Lymph node metastasis
Yes	2 (6.3)
No	30 (93.7)
Vascular tumor thrombus
Yes	2 (6.3)
No	30 (93.7)
Nerve invasion
Yes	2 (6.3)
No	30 (93.7)
VEGF expression
Positive	19 (59.4)
Negative	3 (9.4)
Unknown	10 (31.2)
Microsatellite status
MSS	14 (43.8)
MSI-L	1 (3.1)
Unknown	17 (53.1)
Past use of bevacizumab
Yes	13 (40.6)
No	19 (59.4)
First-line chemotherapy (months), median (rang)	4.72 (0.01-34.73)

BSA: Body surface area; KPS: Karnofsky performance status; PCI: Peritoneal cancer index; CC: Completeness of cytoreduction; VEGF: Vascular endothelial growth factor; MSS: Microsatellite stability; MSI-L: Low microsatellite instability; CEA: Carcinoembryonic antigen.